

Message

From: Krasnic, Toni [/O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=F94B31DB1DBA47189537584F7F0AAAACC-TKRASNIC]
Sent: 7/25/2018 4:14:08 PM
To: cbevan@hsia.org
CC: Norman, Caffey [caffey.norman@squirepb.com]
Subject: FW: TCE study rerun
Attachments: 00459506 Draft Protocol - Updated ver.PSC 20Jun2018.doc

Dear Chris,

Thank you again for sending the TCE study re-run protocol.

Please submit this protocol and any subsequent documents related to this study to the [EPA-HQ-OPPT-2016-0737](#) TCE Docket so it can become part of the record that EPA will review as part of EPA's TCE risk evaluation.

Sincerely,

Toni Krasnic
Existing Chemicals Branch
EPA/OCSP/OPPT/CCD/ECB
WJC East, 4134D | (202) 564-0984

From: Christopher Bevan [mailto:cjbevan@mindspring.com]
Sent: Friday, June 22, 2018 11:27 AM
To: Krasnic, Toni <krasnic.toni@epa.gov>
Cc: Christopher Bevan - CJB Consulting LLC (cbevan@hsia.org) <cbevan@hsia.org>; Norman, Caffey <caffey.norman@squirepb.com>
Subject: Re: TCE study rerun

Dear Toni,

Attached is the final draft protocol for the re-run of the TCE developmental study. The protocol has been sent to us from the CRL Ashland study director in track mode; the changes are mainly the result of a feasibility study that HSIA ran earlier this month. The aim of the feasibility study was to ensure that the dosing solutions could be prepared consistently on a daily basis and to determine whether TCE could be measured in the blood of the dosed pregnant rats. We also wanted to know how much TCE loss would occur from the drinking water bottles over the 24-hour period in the animal cages. We were unable to measure TCE in the blood of pregnant rats given 0.25 and 1,000 ppm TCE in the drinking water; thus, we have removed this measurement from the protocol of the developmental study. We will be providing you with the all of the results of the feasibility in a separate communications. Please let me know if you have any questions.

Kind regards,

Chris

Christopher Bevan PhD DABT
Director, Science Programs
Halogenated Solvents Industry Alliance, Inc.
3033 Wilson Boulevard, Suite 700

Arlington, VA 22201
Phone: 703.875.0684
Cell: 513.646.1468
e-mail: cbevan@hsia.org

From: "Norman, Caffey" <caffey.norman@squirepb.com>
Date: Thursday, June 21, 2018 at 2:38 PM
To: "Krasnic, Toni" <krasnic.toni@epa.gov>
Cc: "Christopher Bevan - CJB Consulting LLC (cbevan@hsia.org)" <cbevan@hsia.org>
Subject: RE: TCE study rerun

Yes, I was informed that we just got a redlined 'final' draft from CRL. As soon as Chris Bevan deems it satisfactory (next few days) he will pass it along to you.

From: Krasnic, Toni <krasnic.toni@epa.gov>
Sent: Thursday, June 21, 2018 2:02 PM
To: Norman, Caffey <caffey.norman@squirepb.com>
Subject: TCE study rerun

Dear Caffey,

Thank you for the update on the TCE study rerun. We're looking forward to receiving the results once they're available in September-October.

As per our discussion yesterday, we'd also like to request an updated protocol of the study, if available.

Sincerely,

Toni Krasnic
Existing Chemicals Branch
EPA/OCSPP/OPPT/CCD/ECB
WJC East, 4134D | (202) 564-0984

From: Norman, Caffey [<mailto:caffey.norman@squirepb.com>]
Sent: Tuesday, May 29, 2018 3:48 PM
To: Morris, Jeff <Morris.Jeff@epa.gov>
Cc: Beck, Nancy <Beck.Nancy@epa.gov>
Subject: FW: Your Comment Submitted on [Regulations.gov](https://www.regulations.gov) (ID: EPA-HQ-OA-2018-0259-0001)

Hi Nancy and Jeff,

Just wanted you to have this comment, which was submitted to the transparency proposal docket. I tried to put it in the TCE TSCA dockets (EPA-HQ-OPPT-2016-0387; EPA-HQ-OPPT-2016-0737; EPA-HQ-OPPT-2016-0163) but they are closed. Jeff, can you get it in?

This is the latest info available on the TCE study rerun. We expect to have an article on the difficulties of administration and how they have been addressed to submit for publication as soon as CRL concludes a preliminary study. Then, as noted, we should have results to share in September-October.



W. Caffey Norman
Partner
Squire Patton Boggs (US) LLP

2550 M Street, NW
Washington, DC 20037
T +1 202 457 5270
F +1 202 457 6315
M +1 202 460 9495

47 Offices in 20 Countries

This message is confidential and may be legally privileged or otherwise protected from disclosure. If you are not the intended recipient, please telephone or email the sender and delete this message and any attachment from your system; you must not copy or disclose the contents of this message or any attachment to any other person.

For information about how Squire Patton Boggs processes EU personal data that is subject to the requirements of the EU General Data Protection Regulation, please see our Privacy Notice regarding the processing of EU personal data about clients and other business contacts pursuant to the GDPR at www.squirepattonboggs.com.

Squire Patton Boggs (US) LLP is part of the international legal practice Squire Patton Boggs, which operates worldwide through a number of separate legal entities. Please visit www.squirepattonboggs.com for more information.

#US
